Renalytix Plc (AIM:RENX)

Market Cap	8.30M -65.4%
Revenue (ttm)	2.45M +40.3%
Net Income	-14.79M
EPS	-0.04
Shares Out	437.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	338,762
Open	2.000
Previous Close	1.900
Day's Range	1.860 - 2.000
52-Week Range	1.600 - 15.500
Beta	1.81
Analysts	Strong Buy
Price Target	82.56 (+4,338.71%)
Earnings Date	Jun 24, 2026

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl...

• Industry: Medical - Healthcare Information Services
• Sector: Healthcare
• Founded: 2018
• Employees: 46
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: RENX

Financial Performance

In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 17, 2026

Data Sources Report a data error